ArticleRMD open2026
Integration of synovial pathotypes and serum proteomic modules as determinants of disease progression and therapeutic response in early rheumatoid arthritis.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is characterised by marked clinical, histological and molecular heterogeneity, complicating treatment-response prediction. This study evaluated associations between synovial pathotypes, pathotype-associated serum proteomic patterns and 6-month clinical outcomes in early RA.
methodsA total of 147 patients with early RA were included in two independent cohorts. In cohort 1, 25 patients underwent synovial biopsy for histological classification by synovial pathotype and Krenn synovitis score. Serum samples collected at biopsy were analysed using the Olink Inflammation panel. Cohort 2, comprising 122 patients, was used to assess the directional consistency of associations between predefined serum proteomic scores and 6-month European Alliance of Associations for Rheumatology (EULAR) response.
resultsThe lymphomyeloid pathotype was associated with higher disease activity, autoantibody positivity and increased synovial immune infiltration. High Krenn score was also associated with greater inflammatory burden and higher disease activity. However, no significant differences in treatment response were observed according to Krenn score, whereas synovial pathotype was associated with differences in biological or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) initiation and exploratory 6-month response patterns. Pathotype-associated serum protein patterns identified in cohort 1 showed differential distributions across histological groups. Higher lymphomyeloid scores were observed among conventional synthetic disease-modifying antirheumatic drug responders, whereas higher diffuse-myeloid scores were observed among b/tsDMARD non-responders. These treatment-stratified associations were exploratory and directionally consistent after adjustment in cohort 2, although neither reached statistical significance.
conclusionSynovial pathotypes in early RA were associated with distinct circulating proteomic patterns reflecting tissue-level heterogeneity. This tissue-to-blood approach supports development of pathotype-associated serum profiles as candidate minimally invasive biomarkers and provides a promising framework for precision medicine in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.